143 related articles for article (PubMed ID: 29069110)
1. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition.
Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS
Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
4. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms.
Soares CN; Frey BN; Haber E; Steiner M
J Clin Psychopharmacol; 2010 Oct; 30(5):612-5. PubMed ID: 20814317
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
Freeman MP; Hirschberg AM; Wang B; Petrillo LF; Connors S; Regan S; Joffe H; Cohen LS
Maturitas; 2013 Jun; 75(2):170-4. PubMed ID: 23602542
[TBL] [Abstract][Full Text] [Related]
6. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial.
Freeman MP; Hibbeln JR; Silver M; Hirschberg AM; Wang B; Yule AM; Petrillo LF; Pascuillo E; Economou NI; Joffe H; Cohen LS
Menopause; 2011 Mar; 18(3):279-84. PubMed ID: 21037490
[TBL] [Abstract][Full Text] [Related]
8. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
McIntyre RS; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
[TBL] [Abstract][Full Text] [Related]
11. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
Baldwin DS; Hansen T; Florea I
Curr Med Res Opin; 2012 Oct; 28(10):1717-24. PubMed ID: 22978748
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
14. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huang IC; Chang TS; Chen C; Sung JY
Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
16. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
17. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
Christensen MC; Schmidt SN; Grande I
J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
[TBL] [Abstract][Full Text] [Related]
19. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
Jacobsen P; Zhong W; Xu R; Nomikos G
J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
[TBL] [Abstract][Full Text] [Related]
20. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
